MPE
MCID: MYL067
MIFTS: 34

Myeloproliferative Disorder, Chronic, with Eosinophilia (MPE)

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Myeloproliferative Disorder, Chronic, with Eosinophilia

MalaCards integrated aliases for Myeloproliferative Disorder, Chronic, with Eosinophilia:

Name: Myeloproliferative Disorder, Chronic, with Eosinophilia 57 40 72
Myeloproliferative Disorder with Eosinophilia 57 13
Mpe 57 74
Myeloproliferative Disorder Chronic with Eosinophilia 74
Chronic Myeloproliferative Disease, Unclassifiable 59
Undifferentiated Myeloproliferative Disease 59
Myeloproliferative Neoplasm, Unclassifiable 72
Eosinophils, Malignant Proliferation of 57
Malignant Proliferation of Eosinophils 74
Malignant Eosinophil Proliferation 29
Mpe; Emp 57
Cmpd-U 59
Emp 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant (12p13)


HPO:

32
myeloproliferative disorder, chronic, with eosinophilia:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 131440
ICD10 via Orphanet 34 D47.1
Orphanet 59 ORPHA86830
MedGen 42 C1851585
UMLS 72 C1333046 C1851585

Summaries for Myeloproliferative Disorder, Chronic, with Eosinophilia

UniProtKB/Swiss-Prot : 74 Myeloproliferative disorder chronic with eosinophilia: A hematologic disorder characterized by malignant eosinophils proliferation.

MalaCards based summary : Myeloproliferative Disorder, Chronic, with Eosinophilia, also known as myeloproliferative disorder with eosinophilia, is related to pdgfrb-associated chronic eosinophilic leukemia and extramedullary plasmacytoma. An important gene associated with Myeloproliferative Disorder, Chronic, with Eosinophilia is PDGFRB (Platelet Derived Growth Factor Receptor Beta). The drugs Mercaptopurine and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are eosinophilia and myeloproliferative disorder

More information from OMIM: 131440

Related Diseases for Myeloproliferative Disorder, Chronic, with Eosinophilia

Diseases related to Myeloproliferative Disorder, Chronic, with Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 pdgfrb-associated chronic eosinophilic leukemia 11.5
2 extramedullary plasmacytoma 10.4
3 plasmacytoma 10.4
4 hypereosinophilic syndrome 10.3
5 lung cancer susceptibility 3 10.3
6 myeloma, multiple 10.3
7 vascular disease 10.3
8 myeloproliferative neoplasm 10.3
9 renal cell carcinoma, nonpapillary 10.2
10 hemopericardium 10.2
11 pericardial effusion 10.2
12 benign mesothelioma 10.2
13 pulmonary embolism 10.2
14 multiple sclerosis 10.0
15 thymoma, familial 10.0
16 leukemia, acute lymphoblastic 10.0
17 infective endocarditis 10.0
18 endocarditis 10.0
19 pneumoconiosis 10.0
20 asbestosis 10.0
21 anthracosis 10.0
22 lymphocytic leukemia 10.0
23 infant gynecomastia 10.0
24 neutropenia 10.0
25 gynecomastia 10.0
26 relapsing-remitting multiple sclerosis 10.0
27 glioblastoma multiforme 10.0
28 thymoma 10.0
29 amelanotic melanoma 10.0
30 infertility 10.0
31 lung disease 10.0
32 neuropathy 10.0
33 glioblastoma 10.0
34 glioma 10.0
35 asbestos intoxication 10.0
36 glial tumor 10.0
37 virus-associated trichodysplasia spinulosa 10.0
38 avascular necrosis 10.0
39 chromosomal triplication 10.0
40 primary hypereosinophilic syndrome 9.5 PDGFRB ETV6
41 myofibroma 9.5 PDGFRB ETV6
42 chronic myelomonocytic leukemia 9.5 PDGFRB ETV6
43 bone marrow cancer 9.4 PDGFRB ETV6
44 leukemia, chronic myeloid 9.4 PDGFRB ETV6
45 hematologic cancer 9.3 PDGFRB ETV6
46 myelodysplastic syndrome 9.1 PDGFRB ETV6

Graphical network of the top 20 diseases related to Myeloproliferative Disorder, Chronic, with Eosinophilia:



Diseases related to Myeloproliferative Disorder, Chronic, with Eosinophilia

Symptoms & Phenotypes for Myeloproliferative Disorder, Chronic, with Eosinophilia

Human phenotypes related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

32
# Description HPO Frequency HPO Source Accession
1 eosinophilia 32 HP:0001880
2 myeloproliferative disorder 32 HP:0005547
3 malignant eosinophil proliferation 32 HP:0006782

Symptoms via clinical synopsis from OMIM:

57
Oncology:
malignant eosinophil proliferation

Clinical features from OMIM:

131440

MGI Mouse Phenotypes related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 8.8 ETV6 PDGFRB TP53BP1

Drugs & Therapeutics for Myeloproliferative Disorder, Chronic, with Eosinophilia

Drugs for Myeloproliferative Disorder, Chronic, with Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mercaptopurine Approved Phase 3 50-44-2 667490
2
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
3
Hydroxyurea Approved Phase 3 127-07-1 3657
4
Daunorubicin Approved Phase 3 20830-81-3 30323
5
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
6
Idarubicin Approved Phase 3 58957-92-9 42890
7
Thioguanine Approved Phase 3 154-42-7 2723601
8
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
9
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
12
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
13
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
14
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
15
Polyestradiol phosphate Approved Phase 3 28014-46-2
16
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
17
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Neurotransmitter Agents Phase 3
20 Excitatory Amino Acid Antagonists Phase 3
21 Anesthetics, Dissociative Phase 3
22 Excitatory Amino Acids Phase 3
23 Analgesics Phase 3
24 Peripheral Nervous System Agents Phase 3
25 Keratolytic Agents Phase 3
26 Cola Phase 3
27 Liver Extracts Phase 3
28 Ophthalmic Solutions Phase 3
29 Narcotics Phase 3
30 Central Nervous System Depressants Phase 3
31 Analgesics, Opioid Phase 3
32 Hydrocortisone-17-butyrate Phase 3
33
asparaginase Phase 3
34 Hydrocortisone 17-butyrate 21-propionate Phase 3
35 Hydrocortisone hemisuccinate Phase 3
36 Anesthetics, Intravenous Phase 3
37 Adjuvants, Anesthesia Phase 3
38 Anesthetics Phase 3
39 Anesthetics, General Phase 3
40 Topoisomerase Inhibitors Phase 3
41 Contraceptives, Oral Phase 3
42 Contraceptives, Oral, Combined Phase 3
43 Contraceptive Agents Phase 3
44 Norgestimate, ethinyl estradiol drug combination Phase 3
45 Estradiol 3-benzoate Phase 3
46 Estradiol 17 beta-cypionate Phase 3
47
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
48
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
49
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
50
Levoleucovorin Approved, Investigational Phase 2 68538-85-2

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
2 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
3 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
5 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
6 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
7 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
8 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
9 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
10 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
11 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
12 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
13 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
15 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
16 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
17 Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial Completed NCT00068276 Phase 2
18 Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant Completed NCT00530218 Phase 2 Ganciclovir
19 A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (THALOMID) For The Treatment Of Anemia In Red Blood Cell Transfusion-Dependent Patients With Myelodysplastic Syndromes Completed NCT00030550 Phase 2 thalidomide
20 A Phase II Study on the Effectiveness of Thalomid (Thalidomide) Combined With Procrit (Erythropoietin) for the Treatment of Anemia in Patients With Low and Intermediate Risk-1 (IPSS Score Less Than or Equal to 1.5) Myelodysplastic Syndromes Completed NCT00053001 Phase 2 thalidomide
21 A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers Completed NCT00042822 Phase 2 romidepsin
22 Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies Completed NCT00014495 Phase 1, Phase 2 cytarabine
23 A Phase II Study Of Amifostine In Children With Myelodysplastic Syndrome Completed NCT00098683 Phase 2 amifostine trihydrate
24 A Phase II Study of VNP40101M For Patients With Acute Myelogenous Leukemia Or High-Risk Myelodysplasia Completed NCT00083187 Phase 2 hydroxyurea;laromustine
25 A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS) Completed NCT00072475 Phase 2 vatalanib
26 Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies Completed NCT00627666 Phase 2 busulfan;fludarabine phosphate;leucovorin calcium;methotrexate
27 A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies Completed NCT00014469 Phase 2 busulfan;melphalan;methotrexate;tacrolimus
28 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
29 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide
30 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
31 A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes Completed NCT00045305 Phase 2 Cyclosporine;Methotrexate;Photopheresis;Mycofenolate mofetil;Pentostatin
32 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
33 A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells Completed NCT00085449 Phase 1, Phase 2 cyclosporine;fludarabine phosphate;melphalan;mycophenolate mofetil
34 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
35 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
36 Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation Completed NCT00053196 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
37 A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor Completed NCT00002718 Phase 2 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
38 Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
39 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
40 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
41 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
42 Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
43 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
44 Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm Recruiting NCT01787487 Phase 2 Azacitidine;Ruxolitinib Phosphate
45 A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Recruiting NCT03075826 Phase 2 SGI-110
46 Phase II Trial of Arsenic Trioxide and Dose-Escalated Cholecalciferol in Myelodysplastic Syndrome Terminated NCT00104806 Phase 2 arsenic trioxide
47 Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation Terminated NCT01118013 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
48 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
49 Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
50 Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI) Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole

Search NIH Clinical Center for Myeloproliferative Disorder, Chronic, with Eosinophilia

Genetic Tests for Myeloproliferative Disorder, Chronic, with Eosinophilia

Genetic tests related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

# Genetic test Affiliating Genes
1 Malignant Eosinophil Proliferation 29 PDGFRB

Anatomical Context for Myeloproliferative Disorder, Chronic, with Eosinophilia

MalaCards organs/tissues related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

41
Bone, Bone Marrow, T Cells, Myeloid, Liver, Nk Cells

Publications for Myeloproliferative Disorder, Chronic, with Eosinophilia

Articles related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

# Title Authors PMID Year
1
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. 8
12181402 2002
2
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. 8
8168137 1994
3
Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association. 8
3478077 1987
4
Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. 38
19394693 2009
5
Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia. 38
16343267 2006
6
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. 38
15087377 2004
7
Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. 38
10741923 2000
8
Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12) 38
9639434 1998
9
A myeloproliferative disorder with eosinophilia associated with a unique translocation (3;5). 38
8943895 1996
10
Translocation t(5;12)(q31-q33;p12-p13): a non-random translocation associated with a myeloid disorder with eosinophilia. 38
7803280 1994

Variations for Myeloproliferative Disorder, Chronic, with Eosinophilia

Expression for Myeloproliferative Disorder, Chronic, with Eosinophilia

Search GEO for disease gene expression data for Myeloproliferative Disorder, Chronic, with Eosinophilia.

Pathways for Myeloproliferative Disorder, Chronic, with Eosinophilia

GO Terms for Myeloproliferative Disorder, Chronic, with Eosinophilia

Sources for Myeloproliferative Disorder, Chronic, with Eosinophilia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....